ReviewRespiratory research2018
What have we learned from observational studies and clinical trials of mild to moderate COPD?
Review in Respiratory research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Chronic obstructive pulmonary disease in severe mental illness: A timely diagnosis to advance the process of quitting smoking.European psychiatry : the journal of the Association of European Psychiatrists · 2021Trial
- External validation of an IOS-derived model for airflow obstruction and COPD in a community-based cohort.NPJ primary care respiratory medicine · 2026Article
- Evaluating Cordyceps militaris capsules on post-bronchodilator FEVFrontiers in pharmacology · 2026Article
- Impulse oscillometry-defined airway abnormalities as a treatable trait for mild-to-moderate COPD: a prospective cohort study with 3-year follow-up.ERJ open research · 2025Article
- Real-world effectiveness study of guideline-directed COPD STANDARDized management in patients with chronic obstructive pulmonary disease: a cluster randomised trial design.BMJ open respiratory research · 2025Article
- Demographic and Clinical Characteristics of Mild, Young and Early COPD: A Cross-Sectional Analysis of 5468 Patients.Journal of clinical medicine · 2024Article
- Risk and distribution of chronic obstructive pulmonary disease-related hospitalizations among primary care patients.Canadian family physician Medecin de famille canadien · 2023Article
- Review
- Treatment Patterns, Socioeconomic Status and Clinical Burden in Mild COPD: A Swedish Real-World, Retrospective Cohort Study, the ARCTIC Study.International journal of chronic obstructive pulmonary disease · 2022Article
- Cost Effectiveness of Case Detection Strategies for the Early Detection of COPD.Applied health economics and health policy · 2021Article
- Observational studies assessing the pharmacological treatment of obstructive lung disease: strengths, challenges and considerations for study design.ERJ open research · 2020Review
- Baseline low ALT activity is associated with increased long-term mortality after COPD exacerbations.BMC pulmonary medicine · 2020Article
- Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment.International journal of chronic obstructive pulmonary disease · 2019Observational
- Article
- Early COPD: current evidence for diagnosis and management.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. It is well established that patients with mild to moderate disease represent the majority of patients with COPD, and patients with mild COPD already have measurable physiological impairment with increased morbidity and a higher risk of mortality compared with healthy non-smoking individuals. However, this subpopulation is both underdiagnosed and undertreated. In addition, most clinical trials include cohorts of patients with worse lung function and quality of life, which are very different from the milder patients usually seen in primary care.Clinical trials have shown that mild-moderate COPD patients present an improvement in lung function after treatment with long-acting bronchodilators (LABD). Inhaled therapy has also shown benefits in terms of symptoms, health-related quality of life (HRQL) and exacerbation prevention in this population. Early intervention might have also a positive effect to prevent functional impairment. Nevertheless, there is scarce evidence from randomised clinical trials and real-life studies about the importance of pharmacological treatment in early stages of COPD to improve long-term outcomes. New concepts such as clinically important deterioration may help to investigate the impact of interventions on the natural history of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.